Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management

Fineline Cube Jul 16, 2026
Company Drug

Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus

Fineline Cube Jul 16, 2026
Company Drug

China’s Evopoint Biosciences and UK’s GSK Eye Breakthrough Therapy Designations for Cancer Therapies

Fineline Cube Sep 3, 2024

BEIJING/LONDON—The Center for Drug Evaluation (CDE) in China has indicated that Evopoint Biosciences’ EZH2 inhibitor...

Company Deals

Duality Biotherapeutics Eyes Hong Kong IPO, Bolstering ADC Pipeline and Global Clinical Trials

Fineline Cube Sep 3, 2024

HONG KONG—Duality Biologics, Inc., a Chinese biotechnology company specializing in antibody drug conjugates (ADCs), is...

Company

MicuRx Pharmaceuticals Reports 44% Revenue Growth and Increased R&D Spending in 2024 H1

Fineline Cube Sep 3, 2024

SHANGHAI—MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has released its financial report...

Company Drug

Shandong Buchang Pharmaceuticals’ rhEPO-Fc for CKD Anemia Accepted for Review by China’s CDE

Fineline Cube Sep 3, 2024

BEIJING—The Center for Drug Evaluation (CDE) in China has accepted the market filing for a...

Company Drug

Biocon Biologics Resolves Patent Dispute with J&J, Secures Market Entry for Biosimilar Stelara

Fineline Cube Sep 2, 2024

Biocon Biologics Ltd, the biosimilars division of Indian pharmaceutical company Biocon Ltd (BOM: 532523, NSE:...

Company Drug

Zuellig Pharma Partners with Regeneron for Libtayo Launch in South Korea and Taiwan

Fineline Cube Sep 2, 2024

Singapore-headquartered Zuellig Pharma, a leading healthcare solutions provider, has entered into an agreement with US...

Company Drug

HutchMed Halts China Filing for Gastric Cancer Drug Fruquintinib Following Regulatory Feedback

Fineline Cube Sep 2, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013), a China-based biopharmaceutical company, has announced the withdrawal...

Company Drug

Novo Nordisk to Resubmit Wegovy Heart Failure Application with Updated Clinical Data

Fineline Cube Sep 2, 2024

Denmark’s pharmaceutical giant, Novo Nordisk (NYSE: NVO), has reported significant findings on the efficacy of...

Company Drug

AccurEdit Therapeutics’ Gene-Editing Drug ART001 Clears FDA Hurdle for US Clinical Trials

Fineline Cube Sep 2, 2024

SUZHOU—AccurEdit Therapeutics (Suzhou) Co., Ltd, a leading Chinese specialist in gene editing therapies, has announced...

Company Deals

Hybio Pharmaceutical Inks Licensing Deal with Mullan Pharmaceutical for Liraglutide Biosimilar

Fineline Cube Sep 2, 2024

BEIJING—Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese biopharmaceutical company, has entered into a licensing...

Company Deals

Allist Pharmaceuticals Acquires Jacobio’s G12C Inhibitor and SHP2 Inhibitor Rights for Greater China Region

Fineline Cube Sep 2, 2024

SHANGHAI—Allist Pharmaceuticals Co., Ltd, a Shanghai-based biotech company, has entered into a licensing agreement with...

Company Deals R&D

Baheal Pharmaceutical Group to Establish R&D Center for Myocardial Repair with CAMS Fuwai Hospital

Fineline Cube Sep 2, 2024

BEIJING—Baheal Pharmaceutical Group, a leading healthcare services and distribution company in China, is venturing into...

Company Drug

Bio-Thera Solutions’ BAT2406 Biosimilar Gets Green Light for Clinical Trials in China

Fineline Cube Sep 2, 2024

GUANGZHOU—Bio-Thera Solutions (SHA: 688177), a leading biopharmaceutical company based in Guangzhou, has received approval from...

Policy / Regulatory

NMPA Unveils 82nd Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Sep 2, 2024

The National Medical Products Administration (NMPA) has announced the release of the 82nd batch of...

Policy / Regulatory

Hainan Province Unveils Ambitious Three-Year Plan for Digital Health Innovation and Economy Expansion

Fineline Cube Sep 2, 2024

HAIKOU—The People’s Government of Hainan Province has unveiled the “Hainan Province’s Three Year Action Plan...

Policy / Regulatory

China Expands Medical Insurance Coverage to Include Assisted Reproductive Technology in 19 Regions

Fineline Cube Sep 2, 2024

BEIJING—As of September 1, 2024, a total of 19 provinces, municipalities, and the Xinjiang Production...

Company

BioAge Labs Taps Former GSK CEO Jean-Pierre Garnier as Chairman

Fineline Cube Sep 2, 2024

NEW YORK—BioAge Labs, a US-based biotechnology company specializing in anti-aging therapies, has announced the appointment...

Company Policy / Regulatory

China’s NMPA Suspends Dr. Reddy’s Atomoxetine Imports Amid Quality Concerns

Fineline Cube Sep 2, 2024

BEIJING—The National Medical Products Administration (NMPA) has issued a notification to immediately suspend the import,...

Company

Roche Diagnostics to Double Down on China with RMB 3 Billion Suzhou Plant Expansion

Fineline Cube Sep 2, 2024

SUZHOU—Roche Diagnostics, the Swiss healthcare giant, has entered into a new investment agreement with the...

Company Deals

WuXi Biologics to Acquire Full Control of Vaccine Contract Services Subsidiary for $108.5 Million

Fineline Cube Sep 2, 2024

HONG KONG—WuXi Biologics (HKG: 2269), a leading global open biopharmaceutical technology platform company, has announced...

Posts pagination

1 … 333 334 335 … 695

Recent updates

  • Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management
  • Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus
  • Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset
  • WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028
  • China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management

Company Drug

Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus

Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.